دورية أكاديمية
أعرض في EDS

Characterization of circSCL38A1 as a novel oncogene in bladder cancer via targeting ILF3/TGF-β2 signaling axis.

التفاصيل البيبلوغرافية
العنوان: Characterization of circSCL38A1 as a novel oncogene in bladder cancer via targeting ILF3/TGF-β2 signaling axis.
المؤلفون: Li P; Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, 250033, China.; Shandong Engineering & Technology Research Center for Tumor Marker Detection, Jinan, Shandong, China., Mi Q; Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, 250033, China., Yan S; Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, 250033, China.; Shandong Engineering & Technology Research Center for Tumor Marker Detection, Jinan, Shandong, China., Xie Y; Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, 250033, China., Cui Z; Department of Urology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, 250021, China., Zhang S; Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, 250033, China., Wang Y; Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, 250033, China., Gao H; Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, 250033, China., Wang Y; Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, 250033, China.; Shandong Engineering & Technology Research Center for Tumor Marker Detection, Jinan, Shandong, China.; Shandong Provincial Clinical Medicine Research Center for Clinical Laboratory, Jinan, Shandong, China., Li J; Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, 250033, China. niderouke@163.com.; Shandong Engineering & Technology Research Center for Tumor Marker Detection, Jinan, Shandong, China. niderouke@163.com., Du L; Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, 250033, China. lutaodu@sdu.edu.cn.; Shandong Engineering & Technology Research Center for Tumor Marker Detection, Jinan, Shandong, China. lutaodu@sdu.edu.cn.; Shandong Provincial Clinical Medicine Research Center for Clinical Laboratory, Jinan, Shandong, China. lutaodu@sdu.edu.cn., Wang C; Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, Shandong, 250033, China. cxwang@sdu.edu.cn.; Shandong Engineering & Technology Research Center for Tumor Marker Detection, Jinan, Shandong, China. cxwang@sdu.edu.cn.; Shandong Provincial Clinical Medicine Research Center for Clinical Laboratory, Jinan, Shandong, China. cxwang@sdu.edu.cn.; Shandong Technology Innovation Center for Big Data and Precision Medicine of Cancer, Jinan, 250033, Shandong, China. cxwang@sdu.edu.cn.
المصدر: Cell death & disease [Cell Death Dis] 2023 Jan 25; Vol. 14 (1), pp. 59. Date of Electronic Publication: 2023 Jan 25.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101524092 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-4889 (Electronic) NLM ISO Abbreviation: Cell Death Dis Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Pub. Group
مواضيع طبية MeSH: Nuclear Factor 90 Proteins*/genetics , Nuclear Factor 90 Proteins*/metabolism , RNA, Circular*/genetics , Transforming Growth Factor beta2*/metabolism , Urinary Bladder Neoplasms*/pathology, Animals ; Mice ; Cell Line, Tumor ; Cell Proliferation ; Gene Expression Regulation, Neoplastic ; Oncogenes ; Humans
مستخلص: The regulatory role of circRNAs in cancer metastasis has become a focused issue in recent years. To date, however, the discovery of novel functional circRNAs and their regulatory mechanisms via binding with RBPs in bladder cancer (BC) are still lacking. Here, we screened out circSLC38A1 based on our sequencing data and followed validation with clinical tissue samples and cell lines. Functional assays showed that circSLC38A1 promoted BC cell invasion in vitro and lung metastasis of mice in vivo. By conducting RNA pull-down, mass spectrum, and RIP assays, circSLC38A1 was found to interact with Interleukin enhancer-binding factor 3 (ILF3), and stabilize ILF3 protein via modulating the ubiquitination process. By integrating our CUT&Tag-seq and RNA-seq data, TGF-β2 was identified as the functional target of the circSLC38A1-ILF3 complex. In addition, m6A methylation was enriched in circSLC38A1 and contributed to its upregulation. Clinically, circSLC38A1 was identified in serum exosomes of BC patients and could distinguish BC patients from healthy individuals with a diagnostic accuracy of 0.878. Thus, our study revealed an essential role and clinical significance of circSLC38A1 in BC via activating the transcription of TGF-β2 in an ILF3-dependent manner, extending the understanding of the importance of circRNA-mediated transcriptional regulation in BC metastasis.
(© 2023. The Author(s).)
References: Cell Res. 2020 Feb;30(2):163-178. (PMID: 31772275)
Cell Rep. 2017 Aug 29;20(9):2262-2276. (PMID: 28854373)
Nat Commun. 2019 Jul 19;10(1):3200. (PMID: 31324812)
Oncogene. 2013 Aug 22;32(34):3933-43. (PMID: 22986534)
Cell Death Differ. 2015 Jan;22(1):34-45. (PMID: 25236394)
Nature. 2013 Mar 21;495(7441):333-8. (PMID: 23446348)
Semin Cancer Biol. 2019 Oct;58:100-108. (PMID: 30684535)
Nat Biotechnol. 2014 May;32(5):453-61. (PMID: 24811520)
Cell. 2017 Jun 15;169(7):1187-1200. (PMID: 28622506)
Eur Urol. 2017 Mar;71(3):462-475. (PMID: 27375033)
Hepatology. 2016 Jan;63(1):159-72. (PMID: 26389641)
Gene. 2000 Dec 31;261(2):345-53. (PMID: 11167023)
J Exp Med. 2007 May 14;204(5):971-7. (PMID: 17470640)
Cell Res. 2020 Mar;30(3):211-228. (PMID: 32047269)
Nat Struct Mol Biol. 2015 Mar;22(3):256-64. (PMID: 25664725)
Lancet. 2016 Dec 3;388(10061):2796-2810. (PMID: 27345655)
Cell Res. 2015 Aug;25(8):981-4. (PMID: 26138677)
Nat Commun. 2019 Sep 11;10(1):4119. (PMID: 31511520)
Cell. 2003 Jun 13;113(6):685-700. (PMID: 12809600)
Clin Cancer Res. 2018 Dec 15;24(24):6319-6330. (PMID: 30305293)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Nucleic Acids Res. 2016 Apr 7;44(6):2846-58. (PMID: 26861625)
Wiley Interdiscip Rev RNA. 2015 Mar-Apr;6(2):243-56. (PMID: 25327818)
Lancet Oncol. 2017 May;18(5):567-569. (PMID: 28389317)
Small. 2018 Feb;14(6):. (PMID: 29282861)
Eur Urol. 2017 Jan;71(1):96-108. (PMID: 27370177)
Mol Cancer. 2020 Jun 3;19(1):101. (PMID: 32493389)
Cell Res. 2019 Aug;29(8):628-640. (PMID: 31209250)
Development. 2016 Jun 1;143(11):1838-47. (PMID: 27246710)
Nat Rev Mol Cell Biol. 2017 Jan;18(1):31-42. (PMID: 27808276)
Eur Urol. 2016 Jan;69(1):60-9. (PMID: 26210894)
J Natl Cancer Inst. 2018 Mar 1;110(3):. (PMID: 28903484)
Cell. 2017 Oct 19;171(3):540-556.e25. (PMID: 28988769)
Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):14542-7. (PMID: 25253891)
Aging (Albany NY). 2020 May 26;12(10):9085-9102. (PMID: 32453709)
Urol Int. 2019;102(3):249-261. (PMID: 30463072)
Cancer Res. 2020 Jun 1;80(11):2138-2149. (PMID: 32217695)
Mol Cancer. 2020 Feb 4;19(1):23. (PMID: 32019579)
Nat Plants. 2017 Apr 18;3:17053. (PMID: 28418376)
Oncogene. 2015 Aug 20;34(34):4460-70. (PMID: 25399696)
Lung Cancer. 2018 Feb;116:80-89. (PMID: 29413056)
Nat Commun. 2019 Apr 29;10(1):1930. (PMID: 31036827)
Mol Cancer. 2020 Jun 10;19(1):105. (PMID: 32522202)
Nucleic Acids Res. 2016 Jan 4;44(D1):D209-15. (PMID: 26450965)
Oncogene. 2018 Nov;37(44):5829-5842. (PMID: 29973691)
Theranostics. 2019 May 26;9(12):3526-3540. (PMID: 31281495)
Theranostics. 2017 Jul 22;7(12):3053-3067. (PMID: 28839463)
المشرفين على المادة: 0 (Nuclear Factor 90 Proteins)
0 (RNA, Circular)
0 (Transforming Growth Factor beta2)
تواريخ الأحداث: Date Created: 20230125 Date Completed: 20230130 Latest Revision: 20230324
رمز التحديث: 20230324
مُعرف محوري في PubMed: PMC9876890
DOI: 10.1038/s41419-023-05598-2
PMID: 36697384
قاعدة البيانات: MEDLINE
الوصف
تدمد:2041-4889
DOI:10.1038/s41419-023-05598-2